Thyroid Eye Disease (TED) Clinical Trials
Recent Thyroid Eye Disease (TED) Research and Clinical Trials worth noting:
HORIZON THERAPEUTICS
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED). The first international approval outside of the U.S.
FDA expands teprotumumab indication to include any thyroid eye disease duration, activity.
Research presented at the American Society of Ophthalmic, Plastic, and Reconstructive Surgery annual meeting noted a decrease in eye muscle size for patients with TED who underwent treatment with TEPEZZA (TM), resulting in better eye movement and less double vision.
VIRIDIAN THERAPEUTICS
Viridian Therapeutics is recruiting participants for their THRIVE – TED phase 3 study. Use this link to read the science and results of Viridian studies.
Viridian Therapeutics is requesting your help to develop new therapies for Thyroid Eye Disease (TED). Please see their THRIVE clinical study (PDF).
Viridian announced positive top line results from its ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with TED.
IMMUNOVANT
Immunovant is presently recruiting for a TED clinical research study. Please use this link to learn more.
See “Understanding Thyroid Eye Disease” contributed by Immunovant.
Immunovant announced two new development programs for the drug batoclimab, including one for Graves’ disease.
SLING THERAPEUTICS
For anyone in the TED community interested in participating in research – Sling Therapeutics is currently running the ‘LIDS’ clinical trial, inviting TED patients to explore their eligibility. If you’re over 18, have a diagnosis of Graves’ disease or Hashimoto’s, and are interested in potentially participating in research, check out this link.
If you do qualify to participate, you could receive the study drug and any study-related procedures at no cost. Travel would also be covered. If you have any other questions, don’t hesitate to ask them to a member of the team who will reach out to you upon successful completion of this short prescreener questionnaire.
###
RELATED ARTICLES
April 2023. The Most Urgent Voice in Eye Research – The Patient’s
by Jeff Todd, JD, MS, & Kira N. Baldonado, MPH @ Prevent Blindness.
Click this poster to open print / PDF version.
As part of our 2024 plans, we will be building out a robust section of our website for clinical studies and welcome an annual sponsorship for this purpose.
Please contact Christine if you would like to be the sponsor of this page / program in 2024: hello@tedcommunity.org